Target Name: SUMO2P6
NCBI ID: G100127922
Review Report on SUMO2P6 Target / Biomarker Content of Review Report on SUMO2P6 Target / Biomarker
Other Name(s): SUMO2 pseudogene 6

The Importance of SUMO2P6 as a Drug Target or Biomarker

SUMO2P6, also known as Small Ubiquitin-like Modifier 2 pseudogene 6, is a non-coding RNA molecule that has gained increasing attention in recent years due to its potential as a drug target or biomarker. Non-coding RNAs, once considered as "junk" or "noise" in the genetic code, have emerged as pivotal components of cellular processes and potential therapeutic targets. In this article, we will explore the significance of SUMO2P6 and its potential applications in drug discovery and diagnostics.

Understanding SUMO2P6

SUMO2P6 is derived from a processed pseudogene of the Small Ubiquitin-like Modifier 2 (SUMO2) gene. Pseudogenes are inactive copies of genes that have accumulated mutations over time, rendering them non-functional. Until recently, these pseudogenes were largely disregarded as "genomic fossils" with no biological relevance. However, advances in genomic research have uncovered their potential regulatory roles and their impact on various biological processes.

SUMO2, the parent gene of SUMO2P6, encodes a protein involved in post-translational modification known as SUMOylation. This process involves the attachment of Small Ubiquitin-like Modifier (SUMO) proteins to target proteins, regulating their activity, stability, and localization within the cell. SUMOylation plays a crucial role in numerous cellular functions, including gene expression, DNA repair, and protein quality control.

The Role of SUMO2P6 in Disease

Recent studies have revealed that SUMO2P6 is dysregulated in various diseases, indicating its potential as a therapeutic target or diagnostic biomarker. Aberrant expression of SUMO2P6 has been associated with cancer, neurodegenerative disorders, and cardiovascular diseases.

In cancer, SUMO2P6 has shown both oncogenic and tumor-suppressive properties, depending on the type and context of the malignancy. For example, in breast cancer, SUMO2P6 functions as an oncogene by promoting tumor cell proliferation, migration, and invasion. On the other hand, in gastric cancer, SUMO2P6 acts as a tumor suppressor by inhibiting tumor growth and metastasis. These findings highlight the complex nature of SUMO2P6 and its diverse roles across various cancer types.

In neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, SUMO2P6 has been implicated in the pathogenesis and progression of these conditions. It has been shown to regulate the aggregation and clearance of misfolded proteins, such as amyloid-beta and alpha-synuclein, which are hallmark features of these diseases. By modulating the expression or activity of SUMO2P6, it may be possible to influence the aggregation process and potentially halt or slow down disease progression.

In cardiovascular diseases, SUMO2P6 has emerged as a potential biomarker for the early detection and prognosis of cardiac conditions, such as myocardial infarction and heart failure. It has been found to be differentially expressed in patients with these conditions compared to healthy individuals, suggesting its potential as a non-invasive diagnostic tool. Furthermore, SUMO2P6 may play a role in regulating cardiac hypertrophy and remodeling, contributing to the development and progression of cardiovascular diseases.

Therapeutic Potential of SUMO2P6

Given its dysregulation in various diseases, targeting SUMO2P6 holds promise as a therapeutic strategy. However, developing drugs that directly target non-coding RNAs like SUMO2P6 poses significant challenges. They lack the well-defined protein structures that traditional small molecule drugs typically interact with. Nevertheless, several approaches have been proposed to modulate the activity or expression of non-coding RNAs, including antisense oligonucleotides, RNA interference, and small molecule inhibitors.

Antisense oligonucleotides (ASOs) are short, synthetic DNA or RNA molecules that can specifically bind to complementary RNA sequences, preventing their translation into proteins. ASOs targeting non-coding RNAs have shown promising results in preclinical and clinical studies, with some already approved for clinical use. By designing ASOs specific to SUMO2P6, it may be possible to inhibit its activity, potentially reducing its effects in diseases such as cancer or neurodegenerative disorders.

RNA interference (RNAi) is another strategy to modulate the expression of non-coding RNAs. It involves the introduction of small RNA molecules, known as small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), that bind to complementary RNA sequences, triggering their degradation. However, efficient delivery of siRNAs or shRNAs to target tissues remains a challenge for clinical applications.

Small molecule inhibitors represent a different approach to target non-coding RNAs indirectly. These molecules are designed to interact with proteins involved in non-coding RNA biogenesis or function, disrupting their activity. Developing small molecule inhibitors specific to factors involved in SUMO2P6 regulation could indirectly modulate its levels or activity, providing a potential therapeutic approach to diseases associated with SUMO2P6 dysregulation.


SUMO2P6, a non-coding RNA derived from a processed pseudogene, holds considerable promise as a drug target or biomarker. Dysregulation of SUMO2P6 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Understanding the complex roles of SUMO2P6 and developing strategies to modulate its activity or expression may provide novel therapeutic approaches to combat these diseases. Further research and development in this field will undoubtedly shed more light on the potential therapeutic applications of SUMO2P6.

Protein Name: SUMO2 Pseudogene 6

The "SUMO2P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO2P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SUMO2P8 | SUMO3 | SUMO4 | SUN1 | SUN2 | SUN3 | SUN5 | SUOX | Superoxide dismutase (SOD) | Suppressor of cytokine signaling (SOCS) | SUPT16H | SUPT20H | SUPT20HL1 | SUPT20HL2 | SUPT3H | SUPT4H1 | SUPT5H | SUPT6H | SUPT7L | SUPV3L1 | SURF complex | SURF1 | SURF2 | SURF4 | SURF6 | Survival of motor neuron (SMN) complex | SUSD1 | SUSD2 | SUSD3 | SUSD4 | SUSD5 | SUSD6 | SUV39H1 | SUV39H2 | SUZ12 | SUZ12P1 | SV2A | SV2B | SV2C | SVBP | SVEP1 | SVIL | SVIL-AS1 | SVIL2P | SVIP | SVOP | SVOPL | SWAP complex | SWAP70 | SWI5 | SWI5-SFR1 complex | SWINGN | SWSAP1 | SWT1 | SYAP1 | SYBU | SYCE1 | SYCE1L | SYCE2 | SYCE3 | SYCN | SYCP1 | SYCP2 | SYCP2L | SYCP3 | SYDE1 | SYDE2 | SYF2 | SYK | SYMPK | SYN1 | SYN2 | SYN3 | Synaptotagmin | SYNC | SYNCRIP | Syndecan | SYNDIG1 | SYNDIG1L | SYNE1 | SYNE1-AS1 | SYNE2 | SYNE3 | SYNE4 | SYNGAP1 | SYNGR1 | SYNGR2 | SYNGR3 | SYNGR4 | SYNJ1 | SYNJ2 | SYNJ2BP | SYNM | SYNM-AS1 | SYNPO | SYNPO2 | SYNPO2L | SYNPO2L-AS1 | SYNPR | SYNPR-AS1